id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-259012-rk0sd9i5	Mehta, Hemal	Trends in Real-World Neovascular AMD Treatment Outcomes in the UK	2020-10-14		.txt	text/plain	7092	354	48	PURPOSE: To report trends in real-world outcomes of anti-vascular endothelial growth factor (anti-VEGF) therapy for neovascular age-related macular degeneration (nAMD) in the United Kingdom (UK) over the last decade. The following multipurpose (.mp) search terms and Medical Subject Headings (MeSH) terms where available were used: macular degeneration, age related macula degeneration, AMD, nAMD, neovascular, wet, VEGF, anti-VEGF, ranibizumab, Lucentis, aflibercept, Eylea, bevacizumab, Avastin, visual acuity, visual outcomes, vision, ocular, blindness, registry, database, long term study/studies, observational study/studies, Phase IV study/studies, real world, real-world, United Kingdom, UK, Scotland, Wales, Northern Ireland, England. Predicting visual outcomes in patients treated with aflibercept for neovascular age-related macular degeneration: data from a real-world clinical setting Impact of injection frequency on 5-year real-world visual acuity outcomes of aflibercept therapy for neovascular age-related macular degeneration Realworld visual and clinical outcomes for patients with neovascular age-related macular degeneration treated with intravitreal ranibizumab: an 8-year observational cohort (AMD8)	./cache/cord-259012-rk0sd9i5.txt	./txt/cord-259012-rk0sd9i5.txt